ibrexafungerp
Sign in to saveAlso known as MK-3118, SCY-078, mk-3118, Brexafemme
Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken orally (by mouth). It is also currently undergoing clinical trials for other indications via an intravenous (IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime.
Key facts
- Drug.tradename
- Brexafemme
- Drug.image
- Ibrexafungerp.svg
- Drug.image_class
- skin-invert-image
- Drug.DailyMedID
- Ibrexafungerp
- Drug.pregnancy_category
- Contraindicated
- Drug.routes_of_administration
- oral, intravenous
- Drug.class
- Antifungal
- Drug.ATC_prefix
- J02
- Drug.ATC_suffix
- AX07
- Drug.legal_US
- Rx-only
- Drug.protein_bound
- >99%
- Drug.metabolism
- Hydroxylation (CYP3A4) then conjugation (glucuronidation, sulfation)
- Drug.elimination_half life
- 20 hours
- Drug.index2_label
- as citrate
- Drug.CAS_number
- 1207753-03-4
- Drug.CAS_number2
- 1965291-08-0
- Drug.PubChem
- 46871657
- Drug.PubChem2
- 137552087
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 729.519305624
- Has use
- medication
Show 6 more facts
- canonical SMILES
- CC(C)C(C)C1(CCC2(C3CCC4C5(COCC4(C3=CCC2(C1C(=O)O)C)CC(C5OCC(C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
- chemical formula
- C₄₄H₆₇N₅O₄
- isomeric SMILES
- C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
- pronunciation
- eye-BREX-ah-FUN-jerp
- legal status (medicine)
- boxed warning
- Commons category
- Ibrexafungerp
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Synthesis
- References
- Further reading
- External links
Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken orally (by mouth). It is also currently undergoing clinical trials for other indications via an intravenous (IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime.
Ibrexafungerp acts via inhibition of glucan synthase, which prevents formation of the fungal cell wall.
Excerpted from Wikipedia’s “ibrexafungerp” article, available under the CC BY-SA 4.0 licence.